Kam Zaki on Twitter: "an interim analysis of Phase II study (n=14) showed the combination of pyrotinib and apatinib has an ORR of 35.7% when used as second line treatment in patients
Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
Full article: Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations
![ADCs Showcase Impressive Activity, Second-Line Combos Seek to Raise the Bar in Quest to Target HER2+ NSCLC ADCs Showcase Impressive Activity, Second-Line Combos Seek to Raise the Bar in Quest to Target HER2+ NSCLC](https://cdn.sanity.io/images/0vv8moc6/onclive/e554c4b56fdb451a16133baa7afa43accb67db05-200x275.jpg?fit=crop&auto=format)
ADCs Showcase Impressive Activity, Second-Line Combos Seek to Raise the Bar in Quest to Target HER2+ NSCLC
![FP14.15 Neratinib-Based Combination Therapy in HER2-Mutant Lung Adenocarcinomas: Findings from two International Phase 2 Studies - Journal of Thoracic Oncology FP14.15 Neratinib-Based Combination Therapy in HER2-Mutant Lung Adenocarcinomas: Findings from two International Phase 2 Studies - Journal of Thoracic Oncology](https://www.jto.org/cms/asset/7d9c1cb4-09bc-46c5-8cef-d2c5a017dc60/fx1.jpg)